Interventional Oncology Research Report 2025: Devices & Consumables, Procedures, Cancer, End User Market Analysis and Forecasts 2024-2029
February 27, 2025 11:08 ET
|
Research and Markets
Dublin, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market by Devices & Consumables (RF, Microwave, Cryoablation. Embolization), Procedures (Thermal Ablation, Non-Thermal...
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
February 26, 2025 10:45 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
February 24, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
February 05, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.
Movember investit 4,9 M$ dans 18 subventions destinées à lutter contre les inégalités en matière de santé dans le traitement du cancer de la prostate
February 04, 2025 06:00 ET
|
Movember Canada
TORONTO, 04 févr. 2025 (GLOBE NEWSWIRE) -- Movember est fière d'annoncer son dernier investissement dans le domaine du cancer de la prostate, qui s'élève à plus de 4,9 millions de dollars....
Movember Invests $4.9 Million Into 18 Grants Addressing Health Inequities in Prostate Cancer Care
February 04, 2025 06:00 ET
|
Movember Canada
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Movember is proud to announce its latest prostate cancer investment of over $4.9 million. Eighteen grants (16 proposals and 2 community development grants)...
Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer
January 28, 2025 04:24 ET
|
Curium
Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.
Fusion Biopsy Market to hit USD 2.1 billion by 2034, says Global Market Insights Inc.
January 22, 2025 07:03 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Fusion biopsy market size was valued at USD 829.1 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.9%...
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
January 16, 2025 08:19 ET
|
Biomerica, Inc.
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif.,...
AUA Partners with Pfizer to Launch $1.5 Million RFP to Advance Care for Patients with Advanced Prostate Cancer
January 03, 2025 10:46 ET
|
American Urological Association
BALTIMORE, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The American Urological Association Education and Research, Inc. (AUAER) is proud to announce a collaboration with Pfizer Medical Grants &...